Valneva Initiates Phase 3 Clinical Study for its Chikungunya Vaccine Candidate VLA1553

Valneva announced the initiation of a pivotal Phase 3 clinical trial for its differentiated, single-shot chikungunya vaccine candidate VLA1553.  The sponsor of the first chikungunya vaccine Biologics License Application (BLA) to be approved in the U.S. will be eligible to receive a Priority Review Voucher (PRV).

Read more